DURECT CORPORATION (NASDAQ:DRRX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On March 14, 2017, DURECT Corporation, a Delaware corporation
(DURECT), announced its four quarter and year end 2016 financial
results. This Current Report is filed to disclose nonpublic
information required to be disclosed by Regulation FD. A copy of
DURECTs press release is attached as Exhibit 99.1 hereto and
incorporated by reference herein.
The information concerning financial results in this Form 8-K and
in Exhibit 99.1 shall not be deemed to be filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of that section. The
information concerning financial results in this Form 8-K and in
Exhibit 99.1 shall not be incorporated into any registration
statement or other document filed with the Securities and
Exchange Commission by the company, whether made before or after
the date hereof, regardless of any general incorporation language
in such filing, except as shall be expressly set forth by
specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
|
(d) |
Exhibits |
|
99.1 |
Press Release of DURECT Corporation dated March 14, 2017 |
About DURECT CORPORATION (NASDAQ:DRRX)
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company’s ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products. DURECT CORPORATION (NASDAQ:DRRX) Recent Trading Information
DURECT CORPORATION (NASDAQ:DRRX) closed its last trading session down -0.01 at 1.00 with 281,317 shares trading hands.